Treatment Based Questions: Difference between revisions
Jump to navigation
Jump to search
Aisha Adigun (talk | contribs) |
Aisha Adigun (talk | contribs) |
||
| Line 8: | Line 8: | ||
====Is every patient with a positive COVID-19 test required to be admitted to the hospital?==== | ====Is every patient with a positive COVID-19 test required to be admitted to the hospital?==== | ||
* Not all patients with COVID-19 require hospital admission. Patients whose clinical presentation warrants in-patient clinical management for supportive medical care should be admitted to the hospital under appropriate isolation precautions. | * Not all patients with COVID-19 require hospital admission. Patients whose clinical presentation warrants in-patient clinical management for supportive medical care should be admitted to the hospital under appropriate isolation precautions.<ref name="urlDo patients with confirmed or suspected COVID-19 need to be admitted to the hospital? | FAQ">{{cite web |url=https://covid19.nj.gov/faqs/coronavirus-information/information-for-businesses/do-patients-with-confirmed-or-suspected-covid-19-need-to-be-admitted-to-the-hospital |title=Do patients with confirmed or suspected COVID-19 need to be admitted to the hospital? | FAQ |format= |work= |accessdate=}}</ref> | ||
* Some patients with the initially mild clinical presentation may worsen in the second week of illness. The decision to monitor these patients in the inpatient or outpatient setting should be made on a case-by-case basis. This decision will depend not only on the clinical presentation, but also on the patient’s ability to engage in self-monitoring, the feasibility of safe isolation at home, and the risk of transmission in the patient’s home environment. | * Some patients with the initially mild clinical presentation may worsen in the second week of illness. The decision to monitor these patients in the inpatient or outpatient setting should be made on a case-by-case basis. This decision will depend not only on the clinical presentation, but also on the patient’s ability to engage in self-monitoring, the feasibility of safe isolation at home, and the risk of transmission in the patient’s home environment.<ref name="urlManagement of Patients with Confirmed 2019-nCoV | CDC">{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html |title=Management of Patients with Confirmed 2019-nCoV | CDC |format= |work= |accessdate=}}</ref> | ||
==== Are there any FDA approved drugs(medicines) for COVID-19? ==== | ==== Are there any FDA approved drugs(medicines) for COVID-19? ==== | ||
*Currently there are no FDA-approved medicines specifically approved for the treatment or prevention of COVID-19. During public health emergencies, the FDA may authorize use of unapproved drugs or unapproved uses of approved drugs for life-threatening conditions when there are no adequate, approved, and available options and other conditions are met. This is called an Emergency Use Authorization (EUA). The FDA has issued EUAs for some medicines to be used for certain patients hospitalized with COVID-19. Researchers are studying new drugs, and medicines that are already approved for other health conditions, as possible treatments for COVID-19. The FDA created the Coronavirus Treatment Acceleration Program (CTAP) to use every available method to move new treatments to patients. Additionally, the FDA is working with the National Institutes of Health, drug manufacturers, researchers, and other partners to accelerate the development process for COVID-19 treatments. FDA’s Sentinel System is being used to monitor the use of drugs, describe the course of illness among hospitalized patients, and evaluate the treatment impact of therapies actively being used under real-world conditions. | *Currently there are no FDA-approved medicines specifically approved for the treatment or prevention of COVID-19. During public health emergencies, the FDA may authorize the use of unapproved drugs or unapproved uses of approved drugs for life-threatening conditions when there are no adequate, approved, and available options and other conditions are met. This is called an Emergency Use Authorization (EUA). The FDA has issued EUAs for some medicines to be used for certain patients hospitalized with COVID-19. Researchers are studying new drugs, and medicines that are already approved for other health conditions, as possible treatments for COVID-19. The FDA created the Coronavirus Treatment Acceleration Program (CTAP) to use every available method to move new treatments to patients. Additionally, the FDA is working with the National Institutes of Health, drug manufacturers, researchers, and other partners to accelerate the development process for COVID-19 treatments. FDA’s Sentinel System is being used to monitor the use of drugs, describe the course of illness among hospitalized patients, and evaluate the treatment impact of therapies actively being used under real-world conditions.<ref name="urlUnderstanding the Regulatory Terminology of Potential Preventions and Treatments for COVID-19 | FDA">{{cite web |url=https://www.fda.gov/consumers/consumer-updates/understanding-regulatory-terminology-potential-preventions-and-treatments-covid-19 |title=Understanding the Regulatory Terminology of Potential Preventions and Treatments for COVID-19 | FDA |format= |work= |accessdate=}}</ref> | ||
==== Is Remdesivir approved by the FDA to treat COVID-19? ==== | ==== Is Remdesivir approved by the FDA to treat COVID-19? ==== | ||
* No. Remdesivir is an investigational antiviral drug. It is not currently FDA-approved to treat or prevent any diseases, including COVID-19. Because remdesivir may possibly help very sick patients, the FDA is allowing this drug to be provided to hospitalized patients with severe COVID-19 under an Emergency Use Authorization (EUA) issued May 1, 2020. Under the EUA, health care providers and patients are provided with information about the risks of remdesivir. However, final data from clinical trials included in an FDA application for approval are necessary for us to determine whether the drug is safe and effective in treating COVID-19. | * No. Remdesivir is an investigational antiviral drug. It is not currently FDA-approved to treat or prevent any diseases, including COVID-19. Because remdesivir may possibly help very sick patients, the FDA is allowing this drug to be provided to hospitalized patients with severe COVID-19 under an Emergency Use Authorization (EUA) issued May 1, 2020. Under the EUA, health care providers and patients are provided with information about the risks of remdesivir. However, final data from clinical trials included in an FDA application for approval are necessary for us to determine whether the drug is safe and effective in treating COVID-19.<ref name="urlwww.fda.gov">{{cite web |url=https://www.fda.gov/media/137574/download |title=www.fda.gov |format= |work= |accessdate=}}</ref> | ||
====Are empirical antibiotics recommended for patients suspected with having COVID-19?==== | ====Are empirical antibiotics recommended for patients suspected with having COVID-19?==== | ||
* Several patients with COVID-19 have been reported to present with concurrent community-acquired bacterial pneumonia. Decisions to administer antibiotics to COVID-19 patients should be based on the likelihood of bacterial infection (community-acquired or hospital-acquired), illness severity, and antimicrobial stewardship issues. | * Several patients with COVID-19 have been reported to present with concurrent community-acquired bacterial pneumonia. Decisions to administer antibiotics to COVID-19 patients should be based on the likelihood of bacterial infection (community-acquired or hospital-acquired), illness severity, and antimicrobial stewardship issues.<ref name="urlTen Clinical Tips on COVID-19 for Healthcare Providers Involved in Patient Care | CDC">{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-tips-for-healthcare-providers.html |title=Ten Clinical Tips on COVID-19 for Healthcare Providers Involved in Patient Care | CDC |format= |work= |accessdate=}}</ref> | ||
====What anti-viral medications are available to treat COVID-19?==== | ====What anti-viral medications are available to treat COVID-19?==== | ||
* There are no drugs or other therapeutics presently approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19. Current clinical management includes infection prevention and control measures and supportive care, including supplemental oxygen and mechanical ventilatory support when indicated. There are many ongoing clinical trials in the US and around the world for the treatment of COVID-19. | * There are no drugs or other therapeutics presently approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19. Current clinical management includes infection prevention and control measures and supportive care, including supplemental oxygen and mechanical ventilatory support when indicated. There are many ongoing clinical trials in the US and around the world for the treatment of COVID-19.<ref name="urlTherapeutic Options for COVID-19 Patients | CDC">{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html |title=Therapeutic Options for COVID-19 Patients | CDC |format= |work= |accessdate=}}</ref> | ||
==== Should I take Ivermectin to prevent or treat COVID-19? ==== | ==== Should I take Ivermectin to prevent or treat COVID-19? ==== | ||
* No. While there are approved uses for ivermectin in people and animals, it is not approved for the prevention or treatment of COVID-19. You should not take any medicine to treat or prevent COVID-19 unless it has been prescribed to you by your health care provider and acquired from a legitimate source. A recently released research article described the effect of ivermectin on SARS-CoV-2 in a laboratory setting. These types of laboratory studies are commonly used at an early stage of drug development. Additional testing is needed to determine whether ivermectin might be appropriate to prevent or treat coronavirus or COVID-19. | * No. While there are approved uses for ivermectin in people and animals, it is not approved for the prevention or treatment of COVID-19. You should not take any medicine to treat or prevent COVID-19 unless it has been prescribed to you by your health care provider and acquired from a legitimate source. A recently released research article described the effect of ivermectin on SARS-CoV-2 in a laboratory setting. These types of laboratory studies are commonly used at an early stage of drug development. Additional testing is needed to determine whether ivermectin might be appropriate to prevent or treat coronavirus or COVID-19.<ref name="urlFAQ: COVID-19 and Ivermectin Intended for Animals | FDA">{{cite web |url=https://www.fda.gov/animal-veterinary/product-safety-information/faq-covid-19-and-ivermectin-intended-animals |title=FAQ: COVID-19 and Ivermectin Intended for Animals | FDA |format= |work= |accessdate=}}</ref> | ||
==== Do NSAIDs worsen the course of disease for people with COVID-19? ==== | ==== Do NSAIDs worsen the course of disease for people with COVID-19? ==== | ||
* CDC is currently not aware of scientific evidence establishing a link between NSAIDs (e.g., ibuprofen, naproxen) and worsening of COVID‑19. FDA external, the European Medicines, the World Health Organization, and CDC are continuing to monitor the situation and will review new information on the effects of NSAIDs and COVID-19 disease as it becomes available. For those who wish to use treatment options other than NSAIDs, there are other over-the-counter and prescription medications approved for pain relief and fever reduction. Patients who rely on NSAIDs to treat chronic conditions and have additional questions should speak to their healthcare provider for individualized management. Patients should use NSAIDs, and all medications, according to the product labels and advice of their healthcare professional. | * CDC is currently not aware of scientific evidence establishing a link between NSAIDs (e.g., ibuprofen, naproxen) and worsening of COVID‑19. FDA external, the European Medicines, the World Health Organization, and CDC are continuing to monitor the situation and will review new information on the effects of NSAIDs and COVID-19 disease as it becomes available. For those who wish to use treatment options other than NSAIDs, there are other over-the-counter and prescription medications approved for pain relief and fever reduction. Patients who rely on NSAIDs to treat chronic conditions and have additional questions should speak to their healthcare provider for individualized management. Patients should use NSAIDs, and all medications, according to the product labels and advice of their healthcare professional.<ref name="urlBest Remedy for COVID-19 Is Prevention | | Blogs | CDC">{{cite web |url=https://blogs.cdc.gov/cancer/2020/03/16/best-remedy-for-covid-19-is-prevention/ |title=Best Remedy for COVID-19 Is Prevention | | Blogs | CDC |format= |work= |accessdate=}}</ref> | ||
==== Are There any vaccines or other medical products to prevent COVID-19? ==== | ==== Are There any vaccines or other medical products to prevent COVID-19? ==== | ||
* At this time there is no vaccine to prevent | * At this time there is no vaccine to prevent COVID-19. The FDA is working with the vaccine developers and other researchers and manufacturers to help expedite the development and availability of medical products such as vaccines, antibodies, and drugs to prevent COVID-19.<ref name="urlCOVID-19 Frequently Asked Questions | FDA">{{cite web |url=https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-frequently-asked-questions |title=COVID-19 Frequently Asked Questions | FDA |format= |work= |accessdate=}}</ref> | ||
==== What is convalescent plasma and why is it being investigated to treat COVID-19? ==== | ==== What is convalescent plasma and why is it being investigated to treat COVID-19? ==== | ||
* Convalescent plasma is the liquid part of blood that is collected from patients who have recovered from the novel coronavirus disease, COVID-19, caused by the virus SARS-CoV-2. COVID-19 patients develop antibodies in the blood against the virus. Antibodies are proteins that might help fight the infection. Convalescent plasma is being investigated for the treatment of COVID-19 because there is no approved treatment for this disease and there is some information that suggests it might help some patients recover from COVID-19. Further investigation is still necessary to determine if convalescent plasma might shorten the duration of illness, reduce morbidity, or prevent death associated with COVID-1 | * Convalescent plasma is the liquid part of blood that is collected from patients who have recovered from the novel coronavirus disease, COVID-19, caused by the virus SARS-CoV-2. COVID-19 patients develop antibodies in the blood against the virus. Antibodies are proteins that might help fight the infection. Convalescent plasma is being investigated for the treatment of COVID-19 because there is no approved treatment for this disease and there is some information that suggests it might help some patients recover from COVID-19. Further investigation is still necessary to determine if convalescent plasma might shorten the duration of illness, reduce morbidity, or prevent death associated with COVID-1.<ref name="urlDonate COVID-19 Plasma | FDA">{{cite web |url=https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/donate-covid-19-plasma |title=Donate COVID-19 Plasma | FDA |format= |work= |accessdate=}}</ref> | ||
==Sources== | ==Sources== | ||
Revision as of 15:45, 23 June 2020
|
Frequently Asked Inpatient Questions Microchapter |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]: Associate Editor(s)-in-Chief: Aisha Adigun, B.Sc., M.D.[2]Nuha Al-Howthi, MD[3]Gurmandeep Singh Sandhu,M.B.B.S.[4]
Treatment Based Questions
Following the retraction of the two articles that halted the use of hydroxychloroquine in COVID-19 patients, can I currently administer this medication to patients?
- Currently, hydroxychloroquine is not recommended for use outside of clinical trials.
Is every patient with a positive COVID-19 test required to be admitted to the hospital?
- Not all patients with COVID-19 require hospital admission. Patients whose clinical presentation warrants in-patient clinical management for supportive medical care should be admitted to the hospital under appropriate isolation precautions.[1]
- Some patients with the initially mild clinical presentation may worsen in the second week of illness. The decision to monitor these patients in the inpatient or outpatient setting should be made on a case-by-case basis. This decision will depend not only on the clinical presentation, but also on the patient’s ability to engage in self-monitoring, the feasibility of safe isolation at home, and the risk of transmission in the patient’s home environment.[2]
Are there any FDA approved drugs(medicines) for COVID-19?
- Currently there are no FDA-approved medicines specifically approved for the treatment or prevention of COVID-19. During public health emergencies, the FDA may authorize the use of unapproved drugs or unapproved uses of approved drugs for life-threatening conditions when there are no adequate, approved, and available options and other conditions are met. This is called an Emergency Use Authorization (EUA). The FDA has issued EUAs for some medicines to be used for certain patients hospitalized with COVID-19. Researchers are studying new drugs, and medicines that are already approved for other health conditions, as possible treatments for COVID-19. The FDA created the Coronavirus Treatment Acceleration Program (CTAP) to use every available method to move new treatments to patients. Additionally, the FDA is working with the National Institutes of Health, drug manufacturers, researchers, and other partners to accelerate the development process for COVID-19 treatments. FDA’s Sentinel System is being used to monitor the use of drugs, describe the course of illness among hospitalized patients, and evaluate the treatment impact of therapies actively being used under real-world conditions.[3]
Is Remdesivir approved by the FDA to treat COVID-19?
- No. Remdesivir is an investigational antiviral drug. It is not currently FDA-approved to treat or prevent any diseases, including COVID-19. Because remdesivir may possibly help very sick patients, the FDA is allowing this drug to be provided to hospitalized patients with severe COVID-19 under an Emergency Use Authorization (EUA) issued May 1, 2020. Under the EUA, health care providers and patients are provided with information about the risks of remdesivir. However, final data from clinical trials included in an FDA application for approval are necessary for us to determine whether the drug is safe and effective in treating COVID-19.[4]
Are empirical antibiotics recommended for patients suspected with having COVID-19?
- Several patients with COVID-19 have been reported to present with concurrent community-acquired bacterial pneumonia. Decisions to administer antibiotics to COVID-19 patients should be based on the likelihood of bacterial infection (community-acquired or hospital-acquired), illness severity, and antimicrobial stewardship issues.[5]
What anti-viral medications are available to treat COVID-19?
- There are no drugs or other therapeutics presently approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19. Current clinical management includes infection prevention and control measures and supportive care, including supplemental oxygen and mechanical ventilatory support when indicated. There are many ongoing clinical trials in the US and around the world for the treatment of COVID-19.[6]
Should I take Ivermectin to prevent or treat COVID-19?
- No. While there are approved uses for ivermectin in people and animals, it is not approved for the prevention or treatment of COVID-19. You should not take any medicine to treat or prevent COVID-19 unless it has been prescribed to you by your health care provider and acquired from a legitimate source. A recently released research article described the effect of ivermectin on SARS-CoV-2 in a laboratory setting. These types of laboratory studies are commonly used at an early stage of drug development. Additional testing is needed to determine whether ivermectin might be appropriate to prevent or treat coronavirus or COVID-19.[7]
Do NSAIDs worsen the course of disease for people with COVID-19?
- CDC is currently not aware of scientific evidence establishing a link between NSAIDs (e.g., ibuprofen, naproxen) and worsening of COVID‑19. FDA external, the European Medicines, the World Health Organization, and CDC are continuing to monitor the situation and will review new information on the effects of NSAIDs and COVID-19 disease as it becomes available. For those who wish to use treatment options other than NSAIDs, there are other over-the-counter and prescription medications approved for pain relief and fever reduction. Patients who rely on NSAIDs to treat chronic conditions and have additional questions should speak to their healthcare provider for individualized management. Patients should use NSAIDs, and all medications, according to the product labels and advice of their healthcare professional.[8]
Are There any vaccines or other medical products to prevent COVID-19?
- At this time there is no vaccine to prevent COVID-19. The FDA is working with the vaccine developers and other researchers and manufacturers to help expedite the development and availability of medical products such as vaccines, antibodies, and drugs to prevent COVID-19.[9]
What is convalescent plasma and why is it being investigated to treat COVID-19?
- Convalescent plasma is the liquid part of blood that is collected from patients who have recovered from the novel coronavirus disease, COVID-19, caused by the virus SARS-CoV-2. COVID-19 patients develop antibodies in the blood against the virus. Antibodies are proteins that might help fight the infection. Convalescent plasma is being investigated for the treatment of COVID-19 because there is no approved treatment for this disease and there is some information that suggests it might help some patients recover from COVID-19. Further investigation is still necessary to determine if convalescent plasma might shorten the duration of illness, reduce morbidity, or prevent death associated with COVID-1.[10]
Sources
- ↑ "Do patients with confirmed or suspected COVID-19 need to be admitted to the hospital? | FAQ".
- ↑ "Management of Patients with Confirmed 2019-nCoV | CDC".
- ↑ "Understanding the Regulatory Terminology of Potential Preventions and Treatments for COVID-19 | FDA".
- ↑ "www.fda.gov".
- ↑ "Ten Clinical Tips on COVID-19 for Healthcare Providers Involved in Patient Care | CDC".
- ↑ "Therapeutic Options for COVID-19 Patients | CDC".
- ↑ "FAQ: COVID-19 and Ivermectin Intended for Animals | FDA".
- ↑ "Best Remedy for COVID-19 Is Prevention | | Blogs | CDC".
- ↑ "COVID-19 Frequently Asked Questions | FDA".
- ↑ "Donate COVID-19 Plasma | FDA".